Kevin Pfleger

Professor

  • The University of Western Australia (M519), 35 Stirling Highway,

    6009 Perth

    Australia

Calculated based on number of publications stored in Pure and citations from Scopus

Personal profile

Biography

Professor Kevin Pfleger is Director, Biomedical and Health Innovation at The University of Western Australia (UWA) and the WA Life Sciences Innovation Hub, as well as Head of Molecular Endocrinology and Pharmacology at the UWA Centre for Medical Research (Harry Perkins Institute of Medical Research). He is also Chief Scientific Advisor to Dimerix Limited, an ASX-listed spin-out company from UWA, as well as Scientific Co-Founder of RAGE Biotech. Prof Pfleger was awarded his MA and PhD from Cambridge and Edinburgh Universities respectively, and relocated to Western Australia in October 2002. He was a National Health and Medical Research Council (NHMRC) Peter Doherty Research Fellow from 2005 to 2008, an Australian Research Council (ARC) Future Fellow from 2011 to 2014, and NHMRC RD Wright Fellow (Level 2) from 2015 to 2018. Prof Pfleger was elected as a Fellow of the British Pharmacological Society in 2021.

Roles and responsibilities

Director, Biomedical and Health Innovation

Head of Molecular Endocrinology and Pharmacology

Deputy Director Entrepreneurship of the ARC Centre for Personalised Therapeutics Technologies

President of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT)

Chair of Biodesign Australia

Co-Director of Australian Clinical Entepreneur Program

Member of the International Advisory Group of the British Pharmacological Society

Member of the WA Branch Committee of AusBiotech

Commercialisation Representative on the WAHTN Management Committee

Member of the Life Sciences WA Committee

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being
  • SDG 4 - Quality Education
  • SDG 8 - Decent Work and Economic Growth
  • SDG 9 - Industry, Innovation, and Infrastructure

Education/Academic qualification

Natural Sciences - Pharmacology, MA, University of Cambridge

Molecular Endocrinology and Pharmacology, PhD, Strutural Determinants of GnRH Ligand-Receptor Interactions, University of Edinburgh

External positions

Chief Scientific Advisor, Dimerix Limited

Scientific Co-Founder, RAGE Biotech

Industry keywords

  • Drug Discovery
  • Medicine and Pharma
  • Biotechnology
  • Health

Research expertise keywords

  • Assay technology
  • Endocrinology—receptors
  • Molecular pharmacology
  • Protein interactions
  • Bioluminescence resonance energy transfer (BRET)
  • G protein-coupled receptors (GPCR)
  • Dimerisation
  • Heteromerisation
  • Arrestin

Fingerprint

Dive into the research topics where Kevin Pfleger is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations and top research areas from the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or